Skip to content
Review Open access

Clinical and Prognostic Spectrum of Non-Dilated Left Ventricular Cardiomyopathy: The Role of Genetic Status

Oct 2026 · Cardiogenetics · Vol 16, pp. 24 · 0 citations · 101 references

TL;DR

NDLVC management requires a paradigm shift towards a multi-parametric, genotype-directed framework, where cardiac magnetic resonance tissue characterisation and personalized risk scores are essential to optimize sudden cardiac death prevention.

Abstract

Non-dilated left ventricular cardiomyopathy (NDLVC) presents a unique clinical paradox: patients with nearly identical phenotypes can face radically different clinical outcomes. NDLVC has been recently recognized as a distinct dynamic phenotype within the spectrum of non-ischemic cardiomyopathies, linked by a high risk of life-threatening arrhythmias. Recent advances in genetics have overcome clinical phenotyping in prognostic accuracy. Specifically, gene-specific scores have been introduced to guide primary prevention ICD in high-risk gene carriers. On the other hand, while gene-elusive cases present a more favourable arrhythmic profile, their long-term clinical outcome is more challenging to predict. Despite advancements in therapeutic strategies, the heterogeneity of the disease represents an ongoing dilemma for risk stratification and long-term surveillance. This review offers a comprehensive analysis of NDLVC management in clinical practice, highlighting the profound prognostic divergence between genetic (both in actionable and VUS carriers) and gene-elusive cohorts. By synthesizing current evidence, we aim to clarify how genotype–phenotype correlations influence clinical outcomes and to provide a framework for more personalized approaches in the follow-up and treatment of these distinct patient populations. Furthermore, we address the current lack of standardized guidelines specifically tailored to gene-elusive phenotypes. In conclusion, NDLVC management requires a paradigm shift towards a multi-parametric, genotype-directed framework, where cardiac magnetic resonance tissue characterisation and personalized risk scores are essential to optimize sudden cardiac death prevention. Future research must leverage artificial intelligence and polygenic risk scores (PRSs) to integrate multi-parametric clinical-imaging data and refine risk stratification beyond traditional binary models. Concurrently, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) will be pivotal as a translational platform to clarify VUS pathogenicity, unravel gene-specific arrhythmic mechanisms, and accelerate targeted therapeutic interventions.

Read PDF

Similar papers

Review Open access Oct 2026

Genetic variant spectrum in dilated and non-dilated left ventricular cardiomyopathy

The latest European Society of Cardiology (ESC) guidelines on cardiomyopathies introduced non-dilated left ventricular cardiomyopathy (NDLVC) as a distinct clinical phenotype within a phenotype-based classification framework. Despite growing recognition of this entity, data on its genetic architecture and its pot...

T. Barkan, H. Feldman, D. Viskin et al. · 0 citations
Open access Oct 2026

The “negative” side of cardiomyopathy: phenotype and arrhythmic risk in gene-elusive patients

Although current literature increasingly supports genotype-driven risk stratification in cardiomyopathies, a substantial proportion of patients remain gene-elusive despite comprehensive genetic testing. In this subgroup, clinical phenotype, prognosis, and arrhythmic risk are less clearly defined compared with gen...

M. Martini, L. Iezzi, A. Parodi et al. · 0 citations
Review Open access Oct 2026

Risk stratification in early non-ischaemic cardiomyopathy: the interplay of genetics and cardiac imaging

Preventing sudden cardiac death (SCD) in early non-ischaemic cardiomyopathy (NICM) remains a major clinical challenge. Traditional risk stratification centred on left ventricular ejection fraction (LVEF) poorly captures arrhythmic risk, particularly in early dilated cardiomyopathy (DCM) and non-dilated left ventricular...

A. Kasiakogias, C. Antoniou, T. Tsampras et al. · 0 citations
Review Open access Oct 2026

Clinical and Genetic Characteristics of Hereditary Arrhythmias and Cardiomyopathies in the Middle East

Inherited arrhythmias and cardiomyopathies are leading causes of sudden cardiac death in young individuals. Although global registries and genetic databases have advanced diagnosis and prevention globally, data from the Middle East (ME) remain limited and fragmented. This review synthesizes clinical and genetic evidenc...

O. Ahmad, H. Muhammad, P. Rattanawong et al. · 1 citation
Review Open access Nov 2026

The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies

Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease in which management requires integration of clinical assessment, cardiovascular physiology, multimodality imaging, functional evaluation, and arrhythmic risk. This review examines contemporary evaluation, risk stratification, an...

A. Parodi, B. Baù, G. Piccolboni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.